DelveInsight’s “Inflammatory Myositis Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Inflammatory Myositis, historical and forecasted epidemiology as well as the Inflammatory Myositis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Inflammatory Myositis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Inflammatory Myositis Market Forecast
Some of the key facts of the Inflammatory Myositis Market Report:
-
The Inflammatory Myositis market size was valued approximately USD 589 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
-
The market size across the 7MM is expected to grow at a CAGR of approximately 11.7%, driven by heightened disease awareness and the introduction of emerging therapies.
-
In 2023, Germany and Italy held the largest market sizes among EU countries, with USD 69 million and USD 47 million, respectively, while Spain had the smallest market size at USD 21 million.
-
Japan had a market size of USD 72 million in 2023, but this is expected to shift in the coming forecast period.
-
In 2023, there were approximately 188 thousand diagnosed cases of inflammatory myositis across the 7MM, with 92 thousand cases estimated to be from the US. These numbers are expected to rise over the forecast period.
-
The diagnosed prevalent cases of inflammatory myositis were classified into specific types: PM, DM, and IBM, with 76 thousand, 84 thousand, and 27 thousand cases respectively across the 7MM in 2023. These numbers are expected to rise by 2034.
-
In 2023, the age-specific cases of inflammatory myositis in the EU4 and the UK were categorized as follows: 3 thousand cases in individuals aged 0–17 years, 12 thousand in those aged 18–44 years, 25 thousand in the 45–64 age group, and 29 thousand cases in individuals aged 65 years and older.
-
In 2023, the diagnosed prevalent cases of inflammatory myositis in Japan were further categorized by gender, with 10 thousand cases in males and 15 thousand cases in females.
-
Key Inflammatory Myositis Companies: CSL Behring, Argenx, Priovant Therapeutics/Roivant, Alexion Pharmaceuticals, Pfizer, Horizon Therapeutics, Eli Lilly and Company, Janssen Research & Development, Pfizer, Immunoforge Co. Ltd., Schering-Plough, GlaxoSmithKline, Roche Pharma AG, and others
-
Key Inflammatory Myositis Therapies: Dazukibart (PF-06823859), Hizentra, Efgartigimod, Brepocitinib, Ultomiris, PF-06823859, Daxdilimab, Baricitinib, Nipocalimab, PF-06823859, Froniglutide, Infliximab, Lovaza, Rituximab, and others
-
The Inflammatory Myositis epidemiology based on gender analyzed that females are more susceptible to suffer from Inflammatory myositis when compared to the male population, in the 7MM
-
The Inflammatory Myositis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Inflammatory Myositis pipeline products will significantly revolutionize the Inflammatory Myositis market dynamics.
Inflammatory Myositis Overview
Inflammatory myositis is a group of rare autoimmune disorders characterized by inflammation and weakness of the muscles. These conditions involve inflammation of the muscles (myositis), leading to muscle weakness, pain, and fatigue. There are several types of inflammatory myositis, including polymyositis, dermatomyositis, and inclusion body myositis, each with its own specific features and patterns of muscle involvement.
Get a Free sample for the Inflammatory Myositis Market Report:
https://www.delveinsight.com/report-store/inflammatory-myositis-im-market
Inflammatory Myositis Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Inflammatory Myositis Epidemiology Segmentation:
The Inflammatory Myositis market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
-
Total Prevalence of Inflammatory Myositis
-
Prevalent Cases of Inflammatory Myositis by severity
-
Gender-specific Prevalence of Inflammatory Myositis
-
Diagnosed Cases of Episodic and Chronic Inflammatory Myositis
Download the report to understand which factors are driving Inflammatory Myositis epidemiology trends @ Inflammatory Myositis Epidemiology Forecast
Inflammatory Myositis Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Inflammatory Myositis market or expected to get launched during the study period. The analysis covers Inflammatory Myositis market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Inflammatory Myositis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Inflammatory Myositis Therapies and Key Companies
-
Dazukibart (PF-06823859): Pfizer
-
Hizentra: CSL Behring
-
Efgartigimod: Argenx
-
Brepocitinib: Priovant Therapeutics/Roivant
-
Ultomiris: Alexion Pharmaceuticals
-
PF-06823859: Pfizer
-
Daxdilimab: Horizon Therapeutics
-
Baricitinib: Eli Lilly and Company
-
Nipocalimab: Janssen Research & Development
-
PF-06823859: Pfizer
-
Froniglutide: Immunoforge Co. Ltd.
-
Infliximab: Schering-Plough
-
Lovaza: GlaxoSmithKline
-
Rituximab: Roche Pharma AG
Discover more about therapies set to grab major Inflammatory Myositis market share @ Inflammatory Myositis Treatment Market
Inflammatory Myositis Market Strengths
-
The therapeutic landscape is prolific in determining the efficacy, safety, and tolerability of novel drugs in patients with IM and its various types.
Inflammatory Myositis Market Opportunities
-
The rising data on overall Inflammatory Myositis prevalence and its subtypes is expected to add significantly to the patient pool.
Scope of the Inflammatory Myositis Market Report
-
Study Period: 2020–2034
-
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
-
Key Inflammatory Myositis Companies: CSL Behring, Argenx, Priovant Therapeutics/Roivant, Alexion Pharmaceuticals, Pfizer, Horizon Therapeutics, Eli Lilly and Company, Janssen Research & Development, Pfizer, Immunoforge Co. Ltd., Schering-Plough, GlaxoSmithKline, Roche Pharma AG, and others
-
Key Inflammatory Myositis Therapies: Dazukibart (PF-06823859), Hizentra, Efgartigimod, Brepocitinib, Ultomiris, PF-06823859, Daxdilimab, Baricitinib, Nipocalimab, PF-06823859, Froniglutide, Infliximab, Lovaza, Rituximab, and others
-
Inflammatory Myositis Therapeutic Assessment: Inflammatory Myositis current marketed and Inflammatory Myositis emerging therapies
-
Inflammatory Myositis Market Dynamics: Inflammatory Myositis market drivers and Inflammatory Myositis market barriers
-
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
-
Inflammatory Myositis Unmet Needs, KOL’s views, Analyst’s views, Inflammatory Myositis Market Access and Reimbursement
To know more about Inflammatory Myositis companies working in the treatment market, visit @ Inflammatory Myositis Clinical Trials and Therapeutic Assessment
Table of Contents
1. Inflammatory Myositis Market Report Introduction
2. Executive Summary for Inflammatory Myositis
3. SWOT analysis of Inflammatory Myositis
4. Inflammatory Myositis Patient Share (%) Overview at a Glance
5. Inflammatory Myositis Market Overview at a Glance
6. Inflammatory Myositis Disease Background and Overview
7. Inflammatory Myositis Epidemiology and Patient Population
8. Country-Specific Patient Population of Inflammatory Myositis
9. Inflammatory Myositis Current Treatment and Medical Practices
10. Inflammatory Myositis Unmet Needs
11. Inflammatory Myositis Emerging Therapies
12. Inflammatory Myositis Market Outlook
13. Country-Wise Inflammatory Myositis Market Analysis (2020–2034)
14. Inflammatory Myositis Market Access and Reimbursement of Therapies
15. Inflammatory Myositis Market Drivers
16. Inflammatory Myositis Market Barriers
17. Inflammatory Myositis Appendix
18. Inflammatory Myositis Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/